Granules India (Granules) is an integrated Indian pharmaceutical company. It manufactures Finished Dosages (FDs), Pharmaceutical Formulation Intermediates (PFIs) and Active Pharmaceutical Ingredients (APIs). It caters to more than 300 clients (including some of the prominent branded and generic players) across 75 nations.
View and Valuation
We expect revenue and PAT to grow at a CAGR of 20.8% & 39.8% respectively over FY16-18E. Further, EBITDA margins are expected to improve by 270bps on account of ramp up in PFIs production and limited competition launches. Hence, we initiate Granules with a BUY rating with a TP of Rs.166 based on 15.5x FY18E EPS.
Research Report Granules India Ltd
[fbcomments]
Wealth Conversations – April 2024- Temporary suspension of subscriptions in ” Mirae Asset Global Electric & Autonomous Vehicles ETFs Fund of Fund & Mirae Asset Global X Artificial Intelligence & Technology ETF Fund of Fund
- Merger Announcement: Aditya Birla Sun Life CRISIL IBX AAA Mar 2024 Index Fund
Here is everything that you need to know about Arbitrage Funds- Temporary suspension of subscriptions in “DSP US Treasury Fund of Fund”
